France Bans Hydroxychloroquine For Treating COVID-19 Patients

A bottle and pills of Hydroxychloroquine sit on a counter at Rock Canyon Pharmacy in Provo, Utah, on May 20, 2020. - US President Donald Trump announced May 18 he has been taking hydroxychloroquine for almost two wee... A bottle and pills of Hydroxychloroquine sit on a counter at Rock Canyon Pharmacy in Provo, Utah, on May 20, 2020. - US President Donald Trump announced May 18 he has been taking hydroxychloroquine for almost two weeks as a preventative measure against COVID-19. (Photo by GEORGE FREY / AFP) (Photo by GEORGE FREY/AFP via Getty Images) MORE LESS
|
May 27, 2020 9:00 a.m.

PARIS — The French government has stopped the use of malaria drug hydroxychloroquine for treating COVID-19 patients after a study suggested it doesn’t work and poses health risks.

A decree ending its use for the coronavirus in France was published Wednesday.

The World Health Organization did the same after a study of 100,000 patients worldwide published last week found the drug was ineffective against the virus and tied to a greater risk of death and heart rhythm problems.

The drug has been popular and politically sensitive in France, where it was included in a trial of multiple treatments and used on hospitalized patients.

U.S. President Donald Trump pushed hydroxychloroquine based on early research by prominent French virologist Dr. Didier Raoult suggesting it reduced virus symptoms.

Raoult shrugged off guidance from France’s High Council for Public Health to stop use of the drug, suggesting it’s not important now that the number of infected people is no longer at crisis levels. The council’s recommendation is “one opinion like any other, I don’t care much,” he told France’s LCI television Tuesday night.

Introducing
The TPM Journalism Fund: A New Way To Support TPM
We're launching the TPM Journalism Fund as an additional way for readers and members to support TPM. Every dollar contributed goes toward:
  • -Hiring More Journalists
  • -Providing free memberships to those who cannot afford them
  • -Supporting independent, non-corporate journalism
Are you experiencing financial hardship?
Apply for a free community-supported membership
Comments
advertisement
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Senior Editor:
Special Projects Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front-End Developer:
Senior Designer:
SPECIAL DEAL FOR PAST TPM MEMBERS
40% OFF AN ANNUAL PRIME MEMBERSHIP
REJOIN FOR JUST $30